CEPI Announces New Permanent Board - January 2018
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: CEPI
This press release announces CEPI's permanent board formation. CEPI is relevant to AI safety discussions as a model for international coordination on emerging technology risks, demonstrating how global coalitions can be structured to address catastrophic biological threats — a governance model sometimes referenced in AI risk preparedness discussions.
Metadata
Importance: 8/100press releasenews
Summary
CEPI (Coalition for Epidemic Preparedness Innovations) announced the establishment of its permanent 12-member Board in January 2018, comprising eight independent global health experts and four investor seats. The coalition, founded in 2017, focuses on financing and coordinating vaccine development against epidemic threats. It had secured $620M of its $1B funding target at the time of this announcement.
Key Points
- •CEPI's permanent Board consists of 12 voting members: 8 independent experts and 4 investor representatives named by a newly formed Investors Council.
- •Founded by governments of India and Norway, Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum in 2017.
- •CEPI had issued two Calls for Proposals: one for vaccines against MERS-CoV, Nipah, and Lassa; one for rapid-response platforms for unknown pathogens.
- •The Board includes global health leaders from MSF, Africa CDC, London School of Hygiene & Tropical Medicine, and Takeda Pharmaceutical.
- •CEPI serves as a public-private-philanthropic coordination model for addressing global health threats, potentially informative for AI risk governance structures.
Cached Content Preview
HTTP 200Fetched May 18, 202617 KB
Facebook LinkedIn X Media release, 24 January 2018, London - Coalition for Epidemic Preparedness Innovations
Today, CEPI, the coalition launched one year ago to finance and coordinate the development of new vaccines to prevent and contain epidemics, announces the establishment of its new permanent Board.
The Board includes global leaders who have made extraordinary contributions to protecting and improving health, and who bring a wealth of expertise to CEPI as it moves into the next phase of its development.
CEPI's new Board will have twelve members. Eight seats will be held by independent members, while four seats have been reserved for investors. The independent members are:
Dr Awa Coll-Seck, Minister of State and Former Minister of Health and social welfare of the Republic of Senegal
Jane Halton, (Chair), former Secretary of the Australian Department of Finance
Professor Cherry Gagandeep Kang, Christian Medical College Vellore
Dr Joanne Liu, International President, MSF
Dr John Nkengasong, Director of the Africa Centers for Disease Control and Prevention
Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine
Dr David Reddy, CEO, Medicines for Malaria Venture
Dr Rajeev Venkayya, President, Global Vaccine Business Unit, Takeda Pharmaceutical Company Limited
The four investor seats will be named by CEPI's newly formed Investors Council. It is anticipated that three seats will be held by sovereign investors and one by a philanthropic investor.
I'm delighted to welcome these eminent experts to our Board. This is a seminal moment in CEPI's development as we invest in developing the vaccines and capabilities that the world currently lacks to prepare against future epidemics. CEPI is fortunate to have a Board of this calibre to advise us as we deliver our mission to make the world safer through new vaccines.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic and civil organizations. It was founded in 2017 by the governments of India and Norway, the Bill & Melinda Gates Foundation, Wellcome and the World Economic Forum. To date, CEPI has also received investment from the governments of Germany, Japan, Australia, Belgium, and Canada. It has reached $620m of its target $1bn funding.
The European Commission has announced a contribution in kind of €250M that will support relevant projects through EC mechanisms.
Since its launch in January 2017, CEPI has announced two Calls for Proposals. The first was for candidate vaccines against Mers-CoV, Nipah and Lassa viruses. The second was for the development of platforms that can be used for rapid vaccine development against unknown pathogens.
www.cepi.net
Notes to Editors
CEPI's new permanent Board will consist of 12 voting members:
Eight independent members appointed based on their individual expertise and knowledge
There will be four investor seats which will be named by CEPI's newly formed Investors C
... (truncated, 17 KB total)Resource ID:
4707dd062eacdcd0 | Stable ID: sid_WTCKBNKbPg